Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,210 followers.

RT @Polarbear900R: Pseudo-progression with osimertinib after definitive chemoradiation in unresectable EGFR mut +ve of stage III NSCLC: A c…

18 Sep 2022

Reply Repost Favourite

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable EGFR mut +ve of stage III NSCLC: A case report ✅ As far as we know, we are the first to report pseudoprogression in osimertinib maintenance after definitive chemoradiation

18 Sep 2022

Reply Repost Favourite

New research: Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report: Epidermal growth factor receptor… https://t.co/8KK1

30 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.